Greywolf Therapeutics
Paul Stainer is an experienced finance and business development leader currently serving as Vice President Finance and Business Development at Grey Wolf Therapeutics since March 2024. Stainer is the Founder and CEO of Forever Eleven Consultancy Ltd, a role held since February 2020. Previous roles include International Finance and Operations Lead at Evolus, where responsibilities included building an international aesthetics business and managing an alliance with a Korean partner. Stainer also held the position of Director, CFO and Company Secretary at Vaso Dynamics, focusing on a clinical start-up and drug development. Earlier experiences encompass leadership positions at STERIS, Otsuka Pharmaceutical Companies Europe, Pfizer, and Wyeth, with significant contributions to financial transformation, market launches, and regional operations. Stainer holds a degree in Management Accounting from Southampton College of Higher Education.
This person is not in any teams
Greywolf Therapeutics
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.